355 research outputs found
Is the Woman-Owned Federal Contracting Program a Good Choice for your Business?
Set asides narrow the playing field and increase your chance of winning contracts. A contracting specialist explains the federal government set-aside program for woman-owned businesses and explores the advantages and disadvantages
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
BACKGROUND: Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who were resistant to the second-generation androgen receptor inhibitor enzalutamide had increased programmed death-ligand 1 (PD-L1) expression on circulating antigen-presenting cells. We hypothesized that the addition of PD-1 inhibition in these patients could induce a meaningful cancer response.
METHODS: We evaluated enzalutamide plus the PD-1 inhibitor pembrolizumab in a single-arm phase II study of 28 men with metastatic castration-resistant prostate cancer (mprogressing on enzalutamide alone. Pembrolizumab 200âmg intravenous was given every 3âweeks for four doses with enzalutamide. The primary endpoint was prostate-specific antigen (PSA) decline of â„50%. Secondary endpoints were objective response, PSA progression-free survival (PFS), time to subsequent treatment, and time to death. Baseline tumor biopsies were obtained when feasible, and samples were sequenced and evaluated for the expression of PD-L1, microsatellite instability (MSI), mutational and neoepitope burdens.
RESULTS: Five (18%) of 28 patients had a PSA decline of â„50%. Three (25%) of 12 patients with measurable disease at baseline achieved an objective response. Of the five responders, two continue with PSA and radiographic response after 39.3 and 37.8 months. For the entire cohort, median follow-up was 37 months, and median PSA PFS time was 3.8 months (95%âCI: 2.8 to 9.9 months). Time to subsequent treatment was 7.21 months (95%âCI: 5.1 to 11.1 months). Median overall survival for all patients was 21.9 months (95%âCI: 14.7 to 28 .4 months), versus 41.7 months (95%âCI: 22.16 to not reached (NR)) in the responders. Of the three responders with baseline biopsies, one had MSI high disease with mutations consistent with DNA-repair defects. None had detectable PD-L1 expression.
CONCLUSIONS: Pembrolizumab has activity in mCRPC when added to enzalutamide. Responses were deep and durable and did not require tumor PD-L1 expression or DNA-repair defects.
TRIAL REGISTRATION NUMBER: clinicaltrials.gov (NCT02312557)
The Vehicle, Fall 1970
Vol. 13, No. 1
Table of Contents
A Thought Written in a Locked RoomJudy Huntpage 1
The Eggshell MoonWilliam Probeckpage 2
PoemBarb Parkerpage 3
4/5, May, 1970J. Michael Sainpage 5
A TreeRichard Stickannpage 6
both or noneMichelle Hallpage 6
The TrainSteve Sestinapage 8
Attempted DiscoveryDonald R. Johnsonpage 16
Island of SmokeVerna L. Jonespage 18
AwakeRobert Bladepage 19
PoemMary Klinkerpage 19
In ChurchMuriel Poolpage 21
PoemBarb Parkerpage 21
PoemMichelle Hallpage 22
Pod\u27nerVerna L. Jonespage 23
Rain and Other ThingsCarol Staniecpage 24
PoemAnn Graffpage 24
Examination of StudentdomMelvin Zaloudekpage 26
Women\u27s LiberationTonya Mortonpage 27
Morning Reflections on the Evening NewsPrudence Herberpage 29
Art and Photography Credits
Jim Diaspage 4
Mike Dorseypages 7, 20
David Griffithpages 8, 17, 25
Cover PhotographyMark McKinneyhttps://thekeep.eiu.edu/vehicle/1024/thumbnail.jp
Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study.
PurposeOsteogenesis imperfecta (OI) predisposes people to recurrent fractures, bone deformities, and short stature. There is a lack of large-scale systematic studies that have investigated growth parameters in OI.MethodsUsing data from the Linked Clinical Research Centers, we compared height, growth velocity, weight, and body mass index (BMI) in 552 individuals with OI. Height, weight, and BMI were plotted on Centers for Disease Control and Prevention normative curves.ResultsIn children, the median z-scores for height in OI types I, III, and IV were -0.66, -6.91, and -2.79, respectively. Growth velocity was diminished in OI types III and IV. The median z-score for weight in children with OI type III was -4.55. The median z-scores for BMI in children with OI types I, III, and IV were 0.10, 0.91, and 0.67, respectively. Generalized linear model analyses demonstrated that the height z-score was positively correlated with the severity of the OI subtype (Pâ<â0.001), age, bisphosphonate use, and rodding (Pâ<â0.05).ConclusionFrom the largest cohort of individuals with OI, we provide median values for height, weight, and BMI z-scores that can aid the evaluation of overall growth in the clinic setting. This study is an important first step in the generation of OI-specific growth curves
Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics
Background:
Lipids have critical functions in cellular energy storage, structure and signaling. Many individual lipid molecules have been associated with the evolution of prostate cancer; however, none of them has been approved to be used as a biomarker. The aim of this study is to identify lipid molecules from hundreds plasma apparent lipid species as biomarkers for diagnosis of prostate cancer.
Methodology/Principal Findings:
Using lipidomics, lipid profiling of 390 individual apparent lipid species was performed on 141 plasma samples from 105 patients with prostate cancer and 36 male controls. High throughput data generated from lipidomics were analyzed using bioinformatic and statistical methods. From 390 apparent lipid species, 35 species were demonstrated to have potential in differentiation of prostate cancer. Within the 35 species, 12 were identified as individual plasma lipid biomarkers for diagnosis of prostate cancer with a sensitivity above 80%, specificity above 50% and accuracy above 80%. Using top 15 of 35 potential biomarkers together increased predictive power dramatically in diagnosis of prostate cancer with a sensitivity of 93.6%, specificity of 90.1% and accuracy of 97.3%. Principal component analysis (PCA) and hierarchical clustering analysis (HCA) demonstrated that patient and control populations were visually separated by identified lipid biomarkers. RandomForest and 10-fold cross validation analyses demonstrated that the identified lipid biomarkers were able to predict unknown populations accurately, and this was not influenced by patient's age and race. Three out of 13 lipid classes, phosphatidylethanolamine (PE), ether-linked phosphatidylethanolamine (ePE) and ether-linked phosphatidylcholine (ePC) could be considered as biomarkers in diagnosis of prostate cancer.
Conclusions/Significance:
Using lipidomics and bioinformatic and statistical methods, we have identified a few out of hundreds plasma apparent lipid molecular species as biomarkers for diagnosis of prostate cancer with a high sensitivity, specificity and accuracy
Genome-Wide Interactions with Dairy Intake for Body Mass Index in Adults of European Descent
Scope: Body weight responds variably to the intake of dairy foods. Genetic variation may contribute to interâindividual variability in associations between body weight and dairy consumption.
Methods and results: A genomeâwide interaction study to discover genetic variants that account for variation in BMI in the context of lowâfat, highâfat and total dairy intake in crossâsectional analysis was conducted. Data from nine discovery studies (up to 25 513 European descent individuals) were metaâanalyzed. Twentyâsix genetic variants reached the selected significance threshold (pâinteraction \u3c10â7), and six independent variants (LINC01512ârs7751666, PALM2/AKAP2ârs914359, ACTA2ârs1388, PPP1R12Aârs7961195, LINC00333ârs9635058, AC098847.1ârs1791355) were evaluated metaâanalytically for replication of interaction in up to 17 675 individuals. Variant rs9635058 (128 kb 3â of LINC00333) was replicated (pâinteraction = 0.004). In the discovery cohorts, rs9635058 interacted with dairy (pâinteraction = 7.36 Ă 10â8) such that each serving of lowâfat dairy was associated with 0.225 kg mâ2 lower BMI per each additional copy of the effect allele (A). A second genetic variant (ACTA2ârs1388) approached interaction replication significance for lowâfat dairy exposure.
Conclusion: Body weight responses to dairy intake may be modified by genotype, in that greater dairy intake may protect a genetic subgroup from higher body weight
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that NfL levels in the cerebrospinal fluid (nâ=â187) and serum (nâ=â405) are correlated with one another and are elevated at the presymptomatic stages of familial Alzheimer's disease. Longitudinal, within-person analysis of serum NfL dynamics (nâ=â196) confirmed this elevation and further revealed that the rate of change of serum NfL could discriminate mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked in participants converting from the presymptomatic to the symptomatic stage and was associated with cortical thinning assessed by magnetic resonance imaging, but less so with amyloid-ÎČ deposition or glucose metabolism (assessed by positron emission tomography). Serum NfL was predictive for both the rate of cortical thinning and cognitive changes assessed by the Mini-Mental State Examination and Logical Memory test. Thus, NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer's disease, which supports its potential utility as a clinically useful biomarker
Recommended from our members
Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution.
Body-fat distribution is a risk factor for adverse cardiovascular health consequences. We analyzed the association of body-fat distribution, assessed by waist-to-hip ratio adjusted for body mass index, with 228,985 predicted coding and splice site variants available on exome arrays in up to 344,369 individuals from five major ancestries (discovery) and 132,177 European-ancestry individuals (validation). We identified 15 common (minor allele frequency, MAF â„5%) and nine low-frequency or rare (MAF <5%) coding novel variants. Pathway/gene set enrichment analyses identified lipid particle, adiponectin, abnormal white adipose tissue physiology and bone development and morphology as important contributors to fat distribution, while cross-trait associations highlight cardiometabolic traits. In functional follow-up analyses, specifically in Drosophila RNAi-knockdowns, we observed a significant increase in the total body triglyceride levels for two genes (DNAH10 and PLXND1). We implicate novel genes in fat distribution, stressing the importance of interrogating low-frequency and protein-coding variants
- âŠ